MediciNova (MNOV) Projected to Post Earnings on Thursday

MediciNova (NASDAQ:MNOV - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

MediciNova (NASDAQ:MNOV - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). On average, analysts expect MediciNova to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MediciNova Stock Down 0.7 %

Shares of NASDAQ MNOV traded down $0.01 during trading on Tuesday, reaching $1.50. 2,218 shares of the stock were exchanged, compared to its average volume of 38,378. The business's 50-day moving average price is $1.47 and its 200 day moving average price is $1.78. The company has a market capitalization of $73.57 million, a price-to-earnings ratio of -6.52 and a beta of 0.46. MediciNova has a twelve month low of $1.12 and a twelve month high of $2.55.

Analyst Ratings Changes

MNOV has been the subject of a number of recent analyst reports. StockNews.com started coverage on MediciNova in a research note on Friday. They set a "hold" rating for the company. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of MediciNova in a report on Wednesday, April 9th.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.